
Amgen shares positive phase 3 results for Imdelltra in small cell lung cancer
Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug against local standard-of-care (SOC) chemotherapy in SCLC …